Style | Citing Format |
---|---|
MLA | Mir MR, et al.. "Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications." Middle East Journal of Digestive Diseases, vol. 11, no. 2, 2019, pp. 104-109. |
APA | Mir MR, Lashkari M, Ghalehtaki R, Mir A, Latif AH (2019). Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications. Middle East Journal of Digestive Diseases, 11(2), 104-109. |
Chicago | Mir MR, Lashkari M, Ghalehtaki R, Mir A, Latif AH. "Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications." Middle East Journal of Digestive Diseases 11, no. 2 (2019): 104-109. |
Harvard | Mir MR et al. (2019) 'Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications', Middle East Journal of Digestive Diseases, 11(2), pp. 104-109. |
Vancouver | Mir MR, Lashkari M, Ghalehtaki R, Mir A, Latif AH. Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications. Middle East Journal of Digestive Diseases. 2019;11(2):104-109. |
BibTex | @article{ author = {Mir MR and Lashkari M and Ghalehtaki R and Mir A and Latif AH}, title = {Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications}, journal = {Middle East Journal of Digestive Diseases}, volume = {11}, number = {2}, pages = {104-109}, year = {2019} } |
RIS | TY - JOUR AU - Mir MR AU - Lashkari M AU - Ghalehtaki R AU - Mir A AU - Latif AH TI - Transhiatal Versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; the Impact of Surgical Approach on Postoperative Complications JO - Middle East Journal of Digestive Diseases VL - 11 IS - 2 SP - 104 EP - 109 PY - 2019 ER - |